<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Familial Mediterranean <z:hpo ids='HP_0001945'>fever</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>) is a recessive, autosomal, auto-<z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorder</z:e> characterised by brief, recurring, self-limited episodes of <z:hpo ids='HP_0001945'>fever</z:hpo> and serositis resulting in abdominal, chest, joint and muscular pain; it is the most common of the periodic hereditary <z:hpo ids='HP_0001945'>fevers</z:hpo> and mostly affects Mediterranean populations </plain></SENT>
<SENT sid="1" pm="."><plain>Daily administration of <z:chebi fb="0" ids="23359">colchicine</z:chebi>, a tricyclic <z:chebi fb="13" ids="22315">alkaloid</z:chebi> with anti-microtubule and anti-inflammatory properties, prevents the recurrence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> attacks and the development of secondary (AA) <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, the major long-tem complication of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="23359">Colchicine</z:chebi> is generally safe and well-tolerated; nevertheless, 5-10 % of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> patients do not respond to conventional treatment, while another 2-5 % of patients are <z:chebi fb="0" ids="23359">colchicine</z:chebi>-intolerant because of toxicity issues, leading physicians to search for alternative therapeutic strategies </plain></SENT>
<SENT sid="3" pm="."><plain>Recent new insights into the mechanisms of auto-<z:mp ids='MP_0001845'>inflammation</z:mp> add further proof to the efficacy of IL-1 targeting drugs in <z:chebi fb="0" ids="23359">colchicine</z:chebi> non-responder/intolerant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>A systematic study of relevant literature through PubMed/Medline was performed in order to identify publications reporting IL-1β biological treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment methods, comorbidities, clinical response and side effects in literature case reports were analysed, as well as recent advances in the pathogenesis of auto-<z:mp ids='MP_0001845'>inflammation</z:mp> mechanisms in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> and the causes of <z:chebi fb="0" ids="23359">colchicine</z:chebi> resistance or toxicity in common clinical practice </plain></SENT>
<SENT sid="6" pm="."><plain>The paradigmatic experience of an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> patient with severe <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> mutations (M694V/M694V) suffering from <z:chebi fb="0" ids="23359">colchicine</z:chebi> toxicity and successfully treated with anakinra is also reported </plain></SENT>
<SENT sid="7" pm="."><plain>The present data show that anti-IL-1β biological treatment is actually a therapeutic option for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> patients unresponsive or intolerant to <z:chebi fb="0" ids="23359">colchicine</z:chebi> or in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> patients with concomitant <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
</text></document>